Diagnostic performance of EGFR2, SYPL1, VTN and some biochemical parameters in women with breast cancer: ROC curve analysis and correlation

M. S. Mahdi; N. Q. Kadhim; H. M. S. Hussein; M. A. Faris; S. M. Hasan; N. H. Khedhir

doi:10.15421/0226091

M. S. Mahdi Tikrit University
N. Q. Kadhim Tikrit University
H. M. S. Hussein Northern Technical University
M. A. Faris Northern Technical University
S. M. Hasan The University of Mashreq
N. H. Khedhir Northern Technical University

Keywords: breast cancer, chemotherapy, EGFR2, SYPL1, VTN, cancer diagnostics.

Abstract

Over two million new cases of breast cancer were reported in 2020, making breast cancer the most common cancer among women worldwide. The epidermal growth factor receptor (EGFR) is a vital cell surface receptor involved in cell proliferation and transformation, and its dysregulation is associated with several types of cancer. Synapto phy s in-like protein 1 (SYPL1) is a component of the synapto physin (SYP) family, sometimes referred to as SYPL or panto physin . Vitronectin protein (VTN), also known as S protein or serum dispersion factor, is a vesicular membrane protein found in both neural and non-neural tissues. The study included 90 women aged 30–65 years from Anbar Governorate. They were divided into two groups of 45 women each. The groups consisted of patients diagnosed with breast cancer and healthy women of the same age group as a control group. Serum was isolated and stored at – 20 °C. Quantitative enzyme immunoassay (ELISA) was used to measure EGFR, SYPL1, and VTN levels. The results showed a significant increase in CA 15-3, CA 19-9, VTN, SYPL1 and calcium levels in the breast cancer group compared to the control group. A significant decrease in EGFR2 and magnesium levels was also observed in breast cancer patients compared to the control group. The data showed a strong association between EGFR2, SYPL1, VTN, and breast cancer. The ROC curve results indicate that SYPL1 is the most effe c tive in detecting breast cancer. Based on these findings, it is suggested that circulating EGFR2, SYPL1, and VTN concentrations can be used to monitor treatment and predict breast cancer.

References

Almas, A. (2017). Hypercalcemia in advanced cases of carcinoma breast: Hospital based study. International Surgery Journal, 4(4), 1154.

Alrayah, N., Mak, A., Saeed, O., & Modawe, G. (2022). Correlation between body mass index and serum calcium levels in adults Sudanese people, Gezira State. Iraqi National Journal of Medicine, 4(2), 204–210.

Ballehaninna, U. K., & Chamberlain, R. S. (2012). The clinical utility of serum CA 19-9 in the diagnosis, prognosis and management of pancreatic adenocarcinoma: An evidence based appraisal. Journal of Gastrointestinal Oncology, 3(2), 105–119.

Banys-Paluchowski, M., Witzel, I., Riethdorf, S., Rack, B., Janni, W., Fasching, P. A., Solomayer, E. F., Aktas, B., Kasimir-Bauer, S., Pantel, K., Fehm, T., & Müller, V. (2017). Evaluation of serum epidermal growth factor receptor (EGFR) in correlation to circulating tumor cells in patients with metastatic breast cancer. Scientific Reports, 7, 17307.

Booth, F. W., Chakravarthy, M. V., Gordon, S. E., & Spangenburg, E. E. (2002). Waging war on physical inactivity: using modern molecular ammunition against an ancient enemy. Journal of Applied Physiology, 93(1), 3–30.

Cazet, A., Julien, S., Bobowski, M., Krzewinski-Recchi, M.-A., Harduin-Lepers, A., Groux-Degroote, S., & Delannoy, P. (2010). Consequences of the expression of sialylated antigens in breast cancer. Carbohydrate Research, 345(10), 1377–1383.

Charkhchi, P., Cybulski, C., Gronwald, J., Wong, F. O., Narod, S. A., & Akbari, M. R. (2020). CA125 and ovarian cancer: A comprehensive review. Cancers, 12(12), 3730.

Chen, D.-H., Wu, Q.-W., Li, X.-D., Wang, S.-J., & Zhang, Z.-M. (2017). SYPL1 overexpression predicts poor prognosis of hepatocellular carcinoma and associates with epithelial-mesenchymal transition. Oncology Reports, 38(3), 1533–1542.

Conlan, M., Tomasini, B., Schultz, R., & Mosher, D. (1988). Plasma vitronectin polymorphism in normal subjects and patients with disseminated intravascular coagulation. Blood, 72(1), 185–190.

Darawshi, S., Darawshi, M., & Daoud Naccache, D. (2022). Unusual hypocalcaemia in breast cancer relapse with multiple bone metastasis. Endocrinology, Diabetes and Metabolism Case Reports, 2022, 20-0222.

Ding, Y., Duan, H., Lin, J., & Zhang, X. (2022). YY1 accelerates oral squamous cell carcinoma progression through long non-coding RNA Kcnq1ot1/ microRNA-506-3p/SYPL1 axis. Journal of Ovarian Research, 15(1), 77.

Duffy, M. J. (2006). Serum tumor markers in breast cancer: Are they of clinical value? Clinical Chemistry, 52(3), 345–351.

Duffy, M. J., Duggan, C., Keane, R., Hill, A. D. K., McDermott, E., Crown, J., & O’Higgins, N. (2004). High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: Study of 600 patients with histologically confirmed breast cancer. Clinical Chemistry, 50(3), 559–563.

Ergun, S., Avci, T., Dumur, S., Pekmezci, Y., Uzun, H., Sayılı, U., Kosem, Y. O. T., Simsek, O., & Pekmezci, S. (2025). Synaptophysin-like-1: A novel serum diagnostic marker for pancreatic ductal adenocarcinoma screening, early diagnosis, and prognosis prediction. Journal of Clinical Medicine, 14(11), 3719.

Ferlay, J., Soerjomataram, I., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., Forman, D., & Bray, F. (2014). Cancer incidence and mortality worldwide: Sources, methods and major patterns in Globocan 2012. International Journal of Cancer, 136(5), e359–e386.

Gandhi, T., Zubair, M., & Bhatt, H. (2024). Cancer antigen 125. StatPearls. StatPearls Publishing, Treasure Island.

Gaughran, G., Aggarwal, N., Shadbolt, B., & Stuart-Harris, R. (2020). The utility of the tumor markers CA15.3, CEA, CA-125 and CA19.9 in metastatic breast cancer. Breast Cancer Management, 9(4), bmt50.

Giamougiannis, P., Martin-Hirsch, P. L., & Martin, F. L. (2021). The evolving role of MUC16 (CA125) in the transformation of ovarian cells and the progression of neoplasia. Carcinogenesis, 42(3), 327–343.

Gile, J., Ruan, G., Abeykoon, J., McMahon, M. M., & Witzig, T. (2020). Magnesium: The overlooked electrolyte in blood cancers? Blood Reviews, 44, 100676.

Given, M., Scott, M., Mc Grath, J. P., & Given, H. F. (2000). The predictive of tumour markers CA 15-3, TPS and CEA in breast cancer recurrence. The Breast, 9(5), 277–280.

Grupińska, J., Kycler, W., Dzieniszewski, D., Kaja, E., Kubicka, A., Gryszczyńska, B., Brzeziński, J. J., Iskra, M., Formanowicz, D., Idaszewska, N., Leporowska, E., & Budzyń, M. (2025). The evaluation of serum magnesium and calcium/magnesium ratio in patients with breast cancer receiving adjuvant chemotherapy. Reports of Practical Oncology and Radiotherapy, 30(6), 816–827.

Hameed, B. H., Al-Rayahi, I. A., & Muhsin, S. S. (2022). Evaluation of preoperative CA15-3 level and its relationship with clinico-pathological characteristics in primary breast cancer patients. Journal of Techniques, 4(2), 21–26.

Hanahan, D., & Weinberg, R. A. (2011). Hallmarks of cancer: The next generation. Cell, 144(5), 646–674.

Hao, W., Zhang, X., Xiu, B., Yang, X., Hu, S., Liu, Z., Duan, C., Jin, S., Ying, X., Zhao, Y., Han, X., Hao, X., Fan, Y., Johnson, H., Meng, D., Persson, J. L., Zhang, H., Feng, X., & Huang, Y. (2016). Vitronectin: A promising breast cancer serum biomarker for early diagnosis of breast cancer in patients. Tumor Biology, 37(7), 8909–8916.

Hashizume, S., Shimoda, M., Yoshinami, T., Abe, K., Masunaga, N., Sota, Y., Miyake, T., Tanei, T., & Shimazu, K. (2022). Hypercalcemia affected in metastatic breast cancer patients without bone metastasis: Report of three cases. Surgical Case Reports, 8(1), 210.

Huang, L., Lin, R., Chen, J., Qi, Y., & Lin, L. (2024). Magnesium ion: A new switch in tumor treatment. Biomedicines, 12(8), 1717.

Huang, W.-Q., Long, W.-Q., Mo, X.-F., Zhang, N.-Q., Luo, H., Lin, F.-Y., Huang, J., & Zhang, C.-X. (2019). Direct and indirect associations between dietary magnesium intake and breast cancer risk. Scientific Reports, 9, 5764.

Ibrahim, N. A., Mohammad, W. J., & Obeid, S. F. (2023). Serum level of tumor marker in breast cancer women in different age groups. Journal Port Science Research, 6(1), 1–3.

Kabir, R. J., Mahmud, R., Kabir, M. E., Ayub Ansary, A. M. A., Sultana, S., Rahman, M., Adhikary, D., Moureen, A., Ranjan, R., & Yusuf, M. A. (2024). Diagnostic accuracy of cancer antigen 15–3 as a seromarker among recurrent breast carcinoma in Bangladesh. Cureus, 16(9), e68448.

Kerr, J. F. R., Wyllie, A. H., & Currie, A. R. (1972). Apoptosis: A basic biological phenomenon with wideranging implications in tissue kinetics. British Journal of Cancer, 26(4), 239–257.

Kirom, U. A., Santosa, B., & Limijadi, E. K. S. (2025). Calcium and CA 15-3 level in breast cancer patients pre- and post-mastectomy surgery. Indonesian Journal of Clinical Pathology and Medical Laboratory, 31(3), 253–256.

Kjær, I. M., Olsen, D. A., Brandslund, I., Bechmann, T., Jakobsen, E. H., Bogh, S. B., & Madsen, J. S. (2020). Dysregulated EGFR pathway in serum in early-stage breast cancer patients: A case control study. Scientific Reports, 10, 6714.

Kosem, Y., Uzun, H., Velidedeoglu, M., Kocael, P., Dumur, S., & Simsek, O. (2024). Clinical significance of serum synaptophysin-like 1 protein levels in breast cancer. Journal of Medical Biochemistry, 43(2), 273–280.

Kurebayashi, J., Nishimura, R., Tanaka, K., Kohno, N., Kurosumi, M., Moriya, T., Ogawa, Y., & Taguchi, T. (2004). Significance of serum tumor markers in monitoring advanced breast cancer patients treated with systemic therapy: A prospective study. Breast Cancer, 11(4), 389–395.

Lax, I., Bellot, F., Howk, R., Ullrich, A., Givol, D., & Schlessinger, J. (1989). Functional analysis of the ligand binding site of EGF-receptor utilizing chimeric chicken/human receptor molecules. The EMBO Journal, 8(2), 421–427.

Leavesley, D. I., Kashyap, A. S., Croll, T., Sivaramakrishnan, M., Shokoohmand, A., Hollier, B. G., & Upton, Z. (2013). Vitronectin – master controller or micromanager? IUBMB Life, 65(10), 807–818.

Luan, Y., Wei, J., Wang, K., Cai, D., Luo, X., Fan, W., Wang, H., & Duan, C. (2021). Comparison of the diagnostic performances of circulating tumor cells and the serum tumor markers CEA, CA125, and CA15-3 for breast cancer: A retrospective case-control study. Journal of Bio-X Research, 4(2), 60–66.

Maeda, I., Tajima, S., Ariizumi, Y., Doi, M., Endo, A., Naruki, S., Hoshikawa, M., Koizumi, H., Kanemaki, Y., Ueno, T., Tsugawa, K., & Takagi, M. (2016). Can synaptophysin be used as a marker of breast cancer diagnosed by core-needle biopsy in epithelial proliferative diseases of the breast? Pathology International, 66(7), 369–375.

Momenimovahed, Z., Mazidimoradi, A., Allahqoli, L., Khalajinia, Z., Salehiniya, H., & Alkatout, I. (2025). Utility of CA-125 for diagnosis and prognosis of breast cancer: A systematic review. Exploration of Targeted Anti-Tumor Therapy, 6, 1002316.

Preissner, K. T., & Seiffert, D. (1998). Role of vitronectin and its receptors in haemostasis and vascular remodeling. Thrombosis Research, 89(1), 1–21.

Ren, X.-H., Yao, Y.-S., He, L.-P., Jin, Y.-L., Chang, W.-W., Li, J., Chen, Y., Song, X.-L., Tang, H., Ding, L.-L., Guo, D.-X., & Li, C.-P. (2013). Overweight and obesity associated with increased total serum calcium level: Comparison of cross-sectional data in the health screening for teaching faculty. Biological Trace Element Research, 156(1–3), 74–78.

Rimawi, M. F., Shetty, P. B., Weiss, H. L., Schiff, R., Osborne, C. K., Chamness, G. C., & Elledge, R. M. (2010). Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes. Cancer, 116(5), 1234–1242.

Roy, R., Schunkert, E. M., Olivova, P., Gilar, M., Geromanos, S., Li, G.-Z., Gebler, J., Dagher, A., El-Hayek, A., Aldakhlallah, R., Staffa, S. J., Zurakowski, D., Lotz, M., Pories, S., & Moses, M. A. (2025). Identification of vitronectin as a potential non-invasive biomarker of metastatic breast cancer using a label-free LC-MS/MS approach. Breast Cancer Research, 27, 94.

Ruzha, Y., Ni, J., Quan, Z., Li, H., & Qing, H. (2022). Role of vitronectin and its receptors in neuronal function and neurodegenerative diseases. International Journal of Molecular Sciences, 23(20), 12387.

Sawada, R., Sun, S.-M., Wu, X., Hong, F., Ragupathi, G., Livingston, P. O., & Scholz, W. W. (2011). Human monoclonal antibodies to Sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity. Clinical Cancer Research, 17(5), 1024–1032.

Shen, J., Zhu, Y., Zhang, S., Lyu, S., Lyu, C., Feng, Z., Hoyle, D. L., Wang, Z. Z., & Cheng, T. (2021). Vitronectin‐activated αvβ3 and αvβ5 integrin signalling specifies haematopoietic fate in human pluripotent stem cells. Cell Proliferation, 54(4), e13012.

Spataro, V., Norbury, C., & Harris, A. (1998). The ubiquitin-proteasome pathway in cancer. British Journal of Cancer, 77(3), 448–455.

Tarighati, E., Keivan, H., & Mahani, H. (2022). A review of prognostic and predictive biomarkers in breast cancer. Clinical and Experimental Medicine, 23(1), 1–16.

Tas, F., Bilgin, E., Karabulut, S., & Duranyildiz, D. (2015). Clinical significance of serum epidermal growth factor receptor (EGFR) levels in patients with breast cancer. Cytokine, 71(1), 66–70.

Tsujii, T., Ogaki, T., Nakae, K., Imai, K., Kise, D., Tada, S., Ueda, H., & Moriyama, M. (2016). Correlation between blood magnesium and calcium concentration in patients treated with an anti-EGFR antibody. Journal of Pharmaceutical Health Care and Sciences, 2, 23.

Walker, R. A., & Day, S. J. (1986). Expression of the antigen detected by the monoclonal antibody Ca 19.9 in human breast tissues. Virchows Archiv A Pathological Anatomy and Histopathology, 409(3), 375–383.

Wang, Y., Zhang, C., Huang, Y., Xu, Q., Zhang, X., & Wang, Y. (2026). Expression characteristics of SYPL1 in oral squamous cell carcinoma and its correlation with prognosis. International Dental Journal, 76, 109326.

Wollman, A. J. M., Fournier, C., Llorente-Garcia, I., Harriman, O., Payne-Dwyer, A. L., Shashkova, S., Zhou, P., Liu, T.-C., Ouaret, D., Wilding, J., Kusumi, A., Bodmer, W., & Leake, M. C. (2022). Critical roles for EGFR and EGFR–HER2 clusters in EGF binding of SW620 human carcinoma cells. Journal of the Royal Society Interface, 19(190), 20220088.

Zagzag, J., Hu, M. I., Fisher, S. B., & Perrier, N. D. (2018). Hypercalcemia and cancer: Differential diagnosis and treatment. CA: A Cancer Journal for Clinicians, 68(5), 377–386.

Zhang, S., Pan, W., Wang, H., Zhi, C., Lin, Y., Wu, P., Ren, Q., Wei, P., Chen, R., Li, F., Xie, Y., Wong, C. K., Tang, H., Cai, Z., Xu, W., & Zeng, H. (2022). Vitronectin, a novel urinary proteomic biomarker, promotes cell pyroptosis in juvenile systemic lupus erythematosus. Mediators of Inflammation, 2022, 8447675.